WO2022029614A1 - Composition comprenant de l'extrait de betterave rouge - Google Patents

Composition comprenant de l'extrait de betterave rouge Download PDF

Info

Publication number
WO2022029614A1
WO2022029614A1 PCT/IB2021/057081 IB2021057081W WO2022029614A1 WO 2022029614 A1 WO2022029614 A1 WO 2022029614A1 IB 2021057081 W IB2021057081 W IB 2021057081W WO 2022029614 A1 WO2022029614 A1 WO 2022029614A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
citrulline
range
salt
arginine
Prior art date
Application number
PCT/IB2021/057081
Other languages
English (en)
Inventor
Edoardo TACCONI
Barbara Politi
Original Assignee
Gensan S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensan S.R.L. filed Critical Gensan S.R.L.
Priority to EP21763125.8A priority Critical patent/EP4192268A1/fr
Publication of WO2022029614A1 publication Critical patent/WO2022029614A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the present invention relates to a composition
  • a composition comprising a red beet extract, citrulline or a salt thereof, and arginine or a salt thereof.
  • the composition administered before training, thanks to its vasodilating properties, allows to significantly improve athletes’ sports performance.
  • the composition is also stable, easily processable, and has an excellent palatability, while being safe and effective for use in sports supplementation.
  • This supplementation allows to optimize energies in the pre-com petition phase and to improve performance of those who practice both endurance and power sports.
  • vasodilation that induces an increase in blood circulation. Since blood is responsible for transporting oxygen, transporting nutrients to the muscles, and removing CO2 and waste metabolites, the increase in blood flow increases the athlete’s ability to work for longer periods, positively impacting on its resistance to fatigue and effort, and also accelerating recovery times.
  • Nitric oxide is physiologically produced by the body through synthesis of the amino acid L- arginine and secreted by the endothelial cells, which cover the inner walls of blood with consequent vasodilation.
  • Nitric oxide also has other important positive effects at the metabolic level, for example on immune response, erectile dysfunction, brain functions such as memory and depression, blood pressure and inflammation, in combating cardiovascular diseases, as well as on mitigation of some consequences resulting from type 2 diabetes, and also positive anti-thrombotic effects.
  • Nitric oxide being a gaseous molecule at room temperature, cannot be directly supplemented due to its chemical nature, in fact there are no supplement containining it, but it is rather generated through administration of precursors thereof.
  • nitric oxide requires the presence of arginine and citrulline (endogenous synthesis), but the human body is able to physiologically synthesize nitric oxide also using nitrates taken with food (exogenous synthesis).
  • L-arginine is an essential amino acid in children and non-essential in adulthood; in addition to being a precursor of nitric oxide in the body, it also helps to reduce accumulation of ammonia formed during physical activity.
  • L-arginine or salts thereof such as hydrochloride
  • L-citrulline is a non-essential amino acid, of the alpha type, involved in the urea cycle and having a direct activity on the immune system.
  • citrulline is also a good remedy for erectile dysfunction and has even anti-atherosclerotic and blood vessel protective activities, as well as increasing the body’s metabolic rate, decreasing muscle fatigue and enhancing aerobic performance. Finally, citrulline is also able to speed up recovery in case of psychophysical stress.
  • Arginine and citrulline have always been used in the world of dietary supplementation, alone or in combination with many other ingredients.
  • US7645742 describes compositions of arginine and citrulline, also in combination with creatinine, D-ribose, L-carnitine, and pyruvate, to increase cellular energy and therefore increase performance, endurance, and intensity of athletes’ physical activities as well as their muscle mass.
  • US7939113 describes compositions based on citrulline in combination with aspartic acid and creatine, optionally also containing L-arginine, L-leucine, or L- valine, again to increase vasodilation in athletes.
  • compositions comprising also arginine and citrulline, having therapeutic purposes, for the treatment of sexual dysfunctions in the first case, and for the treatment of hypertension, cholesterol lowering, and generally for the cardiovascular system health in the second case.
  • nitric oxide As regards the other source of nitric oxide, namely nitrates, they are normally present in green leafy vegetables, and in particular also in red beet, whose juice has been studied precisely due to their high presence.
  • Beet root extract is also known for its effects on cognitive functions, blood pressure, inflammation, and detoxification processes.
  • the aim of the following invention is therefore to provide a product optimized for sports supplementation, in particular for the pre-workout phase, which is capable of promoting vasodilation, has adequate palatability and organoleptic properties and is at the same time easily formulated and processable from an industrial point of view.
  • the inventors of the present invention have surprisingly found that the association of high amounts of red beet extract, in the presence of citrulline or a salt thereof and arginine or a salt thereof, and with particular weight ratios between the beet extract content and the citrulline content, made it possible to obtain a product for athletic supplementation, capable of guaranteeing adequate vasodilation and consequently excellent athletic performance in the subsequent training or competition phase.
  • the invention therefore concerns a composition
  • a composition comprising:
  • red beet extract is present in a concentration higher than 30% by weight and the weight ratio between the red beet extract and citrulline or a salt thereof, expressed as citrulline, is in the range from 1 to 3.
  • a further object of the present invention is also a food supplement comprising the composition of the invention.
  • the invention also concerns the use of the composition of the invention as an ingredient in a food supplement.
  • the invention also concerns the use of the composition of the invention for the preparation of a food supplement.
  • the supplement is in the form of a powder to be reconstituted in water for oral use.
  • the invention also concerns the use of the supplement of the invention to aid or improve vasodilation in a healthy subject before or during physical activity, preferably in the pre-workout phase.
  • the invention concerns a composition
  • a composition comprising:
  • red beet extract is present in a concentration higher than 30% by weight and the weight ratio between the red beet extract and citrulline or a salt thereof, expressed as citrulline, is in the range from 1 to 3.
  • red beet extract is to be understood as an extract, obtained by extraction with water, of leaves and/or roots of red beet, wherein the concentration of nitrates present in said extract is of at least 2% by weight.
  • said extract is obtained from red beet roots.
  • the concentration of nitrates in this extract is of at least 4% by weight, even more preferably at least 6% by weight.
  • red beet extract contains a percentage of oxalates lower than 1 % by weight.
  • any indication of concentration or amount by weight of a certain component is to be understood as referring to the total weight of the composition.
  • the inventors of the present invention have surprisingly found that the selection of these specific ingredients, in the amounts and ratios indicated, allowed to obtain a perfectly balanced product for athletic supplementation, preferably in the pre- workout phase, capable of guaranteeing adequate vasodilation and therefore excellent athletic performance in the subsequent training or competition phase.
  • pre-workout phase is intended to mean the phase preceding the training or competition sessions, or more generally the phase preceding the start of physical exercise.
  • the composition of the invention comprises a red beet extract in a concentration in the range from 40 to 45% by weight.
  • the citrulline or a salt thereof used in the composition of the invention is L-citrulline, even more preferably the L-citrulline DL-malate salt thereof.
  • the arginine or a salt thereof used in the composition of the invention is L-arginine, even more preferably the L-arginine alpha-ketoglutarate salt thereof.
  • the weight ratio between the red beet extract and citrulline or a salt thereof, expressed as citrulline is in the range from 1 .5 to 2.5.
  • the red beet extract concentration was in the range from 40 to 45% by weight, and the weight ratio between the red beet extract and citrulline or a salt thereof, expressed as citrulline, was in the range from 1.5 to 2.5
  • citrulline or a salt thereof is present in a higher amount than arginine or a salt thereof.
  • the weight ratio between the amount of citrulline or a salt thereof and the amount of arginine or a salt thereof, expressed as citrulline and as arginine respectively, is in the range from 2.5 to 3.5, even more preferably of about 3.
  • the inventors of the present invention observed that, when the composition of the invention comprised a red beet extract concentration in the range from 40 to 45% by weight, a weight ratio between the red beet extract and citrulline or a salt thereof, expressed as citrulline, in the range from 1.5 to 2.5 and a weight ratio between the amount of citrulline or a salt thereof and the amount of arginine or a salt thereof, expressed as citrulline and as arginine, respectively, in the range from 2.5 to 3.5 , even more preferably of about 3, the best results in terms of vasodilation during physical activity, preferably in the pre-workout phase, and the best athletic performance in subsequent physical activities were obtained.
  • composition according to the invention comprises a concentration of citrulline or a salt thereof, expressed as citrulline, at least equal to about 15% by weight, more preferably in the range from 15 to 30% by weight, even more preferably in the range from 20 to 25% by weight.
  • the composition according to the invention comprises a concentration of arginine or a salt thereof, expressed as arginine, higher than 5% by weight, more preferably in the range from 7 to 8% by weight.
  • the composition comprises a concentration of red beet extract in the range from 40 to 45% by weight, a concentration of citrulline or a salt thereof, expressed as citrulline, in the range from 20 to 25% by weight, a concentration of arginine or a salt thereof, expressed as arginine, in the range from 7 to 8% by weight.
  • the composition consists of red beet extract, citrulline or a salt thereof and arginine or a salt thereof.
  • the composition according to the invention consists of red beet extract, citrulline or a salt thereof and arginine or a salt thereof
  • the composition comprises a concentration of red beet extract in the range from 45 to 65% by weight, preferably in the range from 48 to 60% by weight, a concentration of citrulline or a salt thereof, expressed as citrulline, in the range from 20 to 35% by weight, preferably in the range from 25 to 32% by weight, a concentration of arginine or a salt thereof, expressed as arginine, in the range from 7 to 12% by weight, preferably in the range from 8 to 11 % by weight.
  • the composition of the invention consists of red beet extract, L-citrulline DL-malate and L-arginine alphaketoglutarate, wherein the concentration of red beet extract is in the range from 48 to 51 % by weight, the concentration of L-citrulline DL-malate, expressed as citrulline, is in the range from 25 to 28% by weight, the concentration of L-arginine alpha-ketoglutarate, expressed as arginine, is in the range from 8 to 9% by weight.
  • composition consisting of red beet extract, citrulline or a salt thereof and arginine or a salt thereof can be effectively used, due to its balanced formula, as an ingredient to be added to other active ingredients or excipients for making more complex formulations, which can be used as food supplements or supplements for sports use.
  • composition of the invention may also contain antioxidants.
  • nitric oxide is a rapidly degraded gas and, therefore, their presence allows an extension of its halflife by reducing the degradation rate and counteracting free radicals.
  • An antioxidant that can be employed for this type of function is, for example, N- acetylcysteine which has an action on glutathione reformation, extending nitric oxide half-life.
  • the composition of the invention further comprises N-acetylcysteine.
  • the composition of the invention comprises N-acetylcysteine in a concentration in the range from 0.5 to 1 % by weight, preferably in the range from 0.6 to 0.8% by weight.
  • the composition comprises a red beet extract in a concentration higher than 30% by weight, a weight ratio between the beet extract and citrulline or a salt thereof, expressed as citrulline, in the range from 1 to 3, a weight ratio between the amount of citrulline or a salt thereof and the amount of arginine or a salt thereof, expressed as citrulline and as arginine, respectively, in the range from 2.5 to 3.5, and N-acetylcysteine in a concentration in the range from 0.6 to 0.8% by weight.
  • composition of the invention may also contain vitamins, mineral salts, carbohydrates, phytonutrients, and generally any other ingredient with a supplementation function.
  • composition of the invention comprises, in particular, carbohydrates.
  • carbohydrates contribute to the recovery of normal muscle function (contraction) after intense and prolonged physical exercise, which leads to muscle fatigue, and depletion of glycogen stores in skeletal muscles.
  • the carbohydrates used in the composition of the invention are highly branched cyclic dextrins.
  • the composition comprises a red beet extract in a concentration higher than 30% by weight, a weight ratio between the red beet extract and citrulline or a salt thereof, expressed as citrulline, in the range from 1 to 3, a weight ratio between the amount of citrulline or a salt thereof and the amount of arginine or a salt thereof, expressed as citrulline and as arginine, respectively, in the range from 2.5 to 3.5, and highly branched cyclic dextrins in a concentration in the range from 6% to 7% by weight.
  • composition of the invention further contains excipients of various types, such as sweeteners, stabilizers, diluents, acidifiers and flavours.
  • sweeteners for example, acesulfame K, sucralose, steviol glycosides or stevia can be mentioned, also in combination with each other.
  • composition of the invention may also comprise stabilizers.
  • the composition of the invention therefore comprises silicon dioxide, which is an agent capable of controlling the composition hygroscopicity.
  • the inventors of the present invention observed that, when silicon dioxide was contained in a concentration equal to at least 2% by weight, preferably about 3%, the composition, in the form of powder, proved to be particularly stable and easily machinable.
  • the composition comprises a red beet extract in a concentration higher than 30% by weight, a weight ratio between the red beet extract and citrulline or a salt thereof, expressed as citrulline, in the range from 1 to 3, a weight ratio between the amount of citrulline or a salt thereof and the amount of arginine or a salt thereof, expressed as citrulline and as arginine, respectively, in the range from 2.5 to 3.5 and silicon dioxide in a concentration of at least about 2%by weight, preferably of about 3%.
  • the composition comprises a concentration of red beet extract in the range from 40 to 45% by weight, a weight ratio between the red beet extract and citrulline or a salt thereof, expressed as citrulline, in the range from 1.5 to 2.5, and a weight ratio between the amount of citrulline or a salt thereof and the amount of arginine or a salt thereof, expressed as citrulline and as arginine, respectively, in the range from 2.5 to 3.5, a concentration of N-acetylcysteine in the range from 0.6 to 0.8% by weight, a concentration of highly branched cyclic dextrins in the range from 6 to 7% by weight and a concentration of silicon dioxide equal to about 3% by weight.
  • composition of the invention was found to be palatable and pleasant to the taste, with excellent organoleptic characteristics, stable, easy to prepare and to produce.
  • the object of the present invention is also a food supplement comprising the composition of the invention.
  • the invention therefore also concerns the use of the composition of the invention for the preparation of a food supplement.
  • composition of the invention can therefore be used as an ingredient of a food supplement to be added together with other active ingredients and/or excipients suitable for the final formulation of the supplement itself.
  • said food supplement is in the form of a powder to be reconstituted for oral administration.
  • said supplement in powder form comprises red beet, L-citrulline DL-malate, L-arginine alpha-ketoglutarate, N- acetyl-L-cysteine, branched cyclic dextrins and silicon dioxide, it is prepared following the method of progressive dilutions, i.e.
  • the sequence of addition of the ingredients is particularly important, and above all the initial presence of an adequate amount of silicon dioxide, an agent present with the aim of containing the hygroscopicity of the mixture and guaranteeing stability and machinability thereof, given the presence of particularly hygroscopic ingredients.
  • Said powder supplement can be advantageously contained in a multidose tin comprising, in addition to the powder composition, a suitable dispenser.
  • the format of said tin may be of 250 g, 500 g or 1000 g of powder, preferably 500 g of powder.
  • the food supplement in powder form has a unitary dosage of 10 g of powder to be reconstituted in 100 ml of water.
  • the dose that the athlete can take will be calculated on the basis of the body weight; typically for an athlete with a body weight of 70-80 kg it is recommended to take a unitary dose of 10 g of supplement to be dissolved in 100 ml of water, for an athlete with a body weight of 80-90 kg it is recommended to take two unitary doses of 10 g, for a total of 20 g of supplement, to be dissolved in 200 ml of water and in the case of an athlete with a body weight of over 90 kg, it is recommended to take three unitary doses of 10 g , for a total of 30 g of supplement, to be dissolved in 300 ml of water.
  • the supplement should preferably be taken about 30-45 minutes before the training or competition session.
  • a further object of the present invention is the use of the supplement of the invention to aid or improve vasodilation in a healthy subject before or during physical activity, preferably in the pre-workout phase.
  • Example 1 Preparation of compositions comprising red beet extract, citrulline and arginine.
  • the red beet extract was an extract commercially available under the trade name Trubeet® sold by Bio-gen.
  • compositions were prepared with the method of progressive dilutions by mixing, in sequence, silicon dioxide, L-citrulline DL-malate, L-arginine alphaketoglutarate and N-acetylcysteine in a time of about 5 minutes.
  • Red beet extract was added to the mixture thus obtained together with flavours and sweeteners, again with the method of progressive dilutions, and mixing for about 10 minutes until a homogeneous mixture was obtained.
  • the sequence of addition of the ingredients was particularly important, and above all the initial presence of an adequate amount of silicon dioxide, an agent present with the aim of containing the hygroscopicity of the mixture and guaranteeing stability and machinability thereof, given the presence of particularly hygroscopic ingredients, such as L- citrulline-DL-malate.
  • mixture B with a higher silicon dioxide content, was more stable and more machinable than mixture A.
  • compositions A and B were dissolved in 100 ml of water and administered to two different groups of 10 athletes (each group consisted of healthy adult subjects aged between 18 and 65 years), about 30-45 minutes before the performance, then visually assessing, at the end of the training session, their vasodilating effect on the muscles, then also observing in particular the relief and definition of the veins on the muscles. Fatigue resistance was also evaluated.
  • the performance evaluations were expressed by the athletes themselves using a rating scale that ranged from unsatisfactory (+) to excellent (+++++). A result ranging from sufficient (+++) to excellent (+++++) was considered acceptable.
  • compositions were also asked to evaluate the palatability of the compositions, using a scale ranging from * (not pleasant enough) to ** (pleasant). Only those compositions that had obtained the ** (pleasant) rating were considered acceptable. In the test, the two compositions were not found to be particularly performing in terms of muscle definition, that was not yet optimal, and therefore the vasodilator effect was not yet the desired one (performance from +++ upwards); however, composition B was better than composition A.
  • compositions C, D, E and F comprising red beet extract, citrulline and arginine, the ingredients listed in the following Table
  • compositions C, D, E and F Ingredients of compositions C, D, E and F
  • the red beet extract was an extract commercially available under the trade name Trubeet® sold by Bio-gen.
  • compositions were prepared with the method of progressive dilutions by mixing, in sequence, silicon dioxide (where present), L-citrulline DL-malate, L- arginine alpha-ketoglutarate and N-acetylcysteine (where present) in a time of about 5 minutes.
  • Red beet extract was added to the mixture thus obtained together with flavours, sweeteners and branched cyclic dextrin, again with the method of progressive dilutions, and mixing for about 10 minutes until a homogeneous mixture was obtained.
  • the sequence of addition of the ingredients was confirmed to be particularly important, above all the initial presence of an adequate amount of silicon dioxide, an agent present with the aim of containing the hygroscopicity of the mixture and guaranteeing stability and machinability thereof, given the presence of particularly hygroscopic ingredients.
  • concentrations of silicon dioxide equal to at least 2% by weight guaranteed the possibility to obtain easily machinable powders, with the right degree of smoothness and a controlled and acceptable hygroscopicity.
  • compositions C, D and E characterized, in addition to high concentrations of red beet extract, always higher than 30% by weight, and in particular between 40 and 45% by weight, also by a weight ratio between the amount of this extract and L-citrulline-DL-malate (expressed as citrulline) between 1.5 and 2.5%, provided performance that met expectations (performance assessed of at least +++ and palatability assessed **).
  • compositions C and E gave the best results (performance evaluated +++++ and ++++, respectively).
  • Composition F that, contrarily to compositions C, D and E, had a much lower percentage by weight of red beet extract was the one which gave the worst performance results.
  • compositions thanks to the presence of appropriate amounts, preferably in the range from 6 to 7% (weight/weight) of highly branched cyclic dextrins, finally proved to be perfectly balanced in terms of energy intake.
  • compositions C, D, E and F also exhibited excellent palatability, a result that had not been possible to achieve, for example, with compositions A and B of Example 1 in which stevia was mainly used as a sweetener.
  • Table 3 provides a summary of the results achieved by the tests in the case of the 6 formulations tested, according to the specific weight percentages of the three main ingredients, as well as their relative weight ratios.
  • composition C was shown to be the best, and therefore the most performing with respect to all observation parameters.
  • Example 3 Preparation of a composition containing red beet extract, L- arginine and L-citrulline.
  • a powder composition G comprising exclusively red beet extract, citrulline and arginine, the ingredients in the percentages listed in the following Table 4 were used.
  • composition G Ingredients of composition G.
  • the red beet extract was an extract commercially available under the trade name Trubeet® sold by Bio-gen.
  • composition was prepared with the method of progressive dilutions by mixing, in sequence, L-citrulline DL-malate and L-arginine alpha-ketoglutarate in a time of about 5 minutes.
  • the red beet extract was then added to the mixture thus obtained, by mixing for about 10 minutes until a homogeneous mixture was obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait de betterave rouge, de la citrulline ou un sel de celle-ci, et de l'arginine ou un sel de celle-ci. En particulier, la composition comprend une concentration d'extrait de betterave rouge supérieure à 30 % en poids, et un rapport pondéral entre l'extrait de betterave rouge et la citrulline ou un sel de celle-ci entre 1 et 3. La composition, administrée avant l'entraînement, grâce à ses propriétés vasodilatatrices, permet d'améliorer significativement les performances sportives des athlètes. La composition est également stable, facile à traiter, et présente une excellente palatabilité, tout en étant sûre et efficace pour une utilisation en tant que supplément sportif.
PCT/IB2021/057081 2020-08-04 2021-08-03 Composition comprenant de l'extrait de betterave rouge WO2022029614A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21763125.8A EP4192268A1 (fr) 2020-08-04 2021-08-03 Composition comprenant de l'extrait de betterave rouge

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT202000019240 2020-08-04
IT102020000019240 2020-08-04

Publications (1)

Publication Number Publication Date
WO2022029614A1 true WO2022029614A1 (fr) 2022-02-10

Family

ID=73139142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/057081 WO2022029614A1 (fr) 2020-08-04 2021-08-03 Composition comprenant de l'extrait de betterave rouge

Country Status (2)

Country Link
EP (1) EP4192268A1 (fr)
WO (1) WO2022029614A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292134A1 (en) * 2005-06-22 2006-12-28 Sidney Stohs Composition for enhancing cellular energy
EP2210600A1 (fr) * 2007-10-10 2010-07-28 Kyowa Hakko Bio Co., Ltd Préparation orale à action rapide pouvant augmenter le taux d'arginine dans le sang contenant de la citrulline et de l'arginine
WO2019183028A1 (fr) * 2018-03-20 2019-09-26 Pro Phase, Inc. Produit nutritionnel et son procédé d'utilisation
WO2020231906A1 (fr) * 2019-05-10 2020-11-19 Bgs Holdings Llc Formulations de compléments alimentaires et pour le sport

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292134A1 (en) * 2005-06-22 2006-12-28 Sidney Stohs Composition for enhancing cellular energy
EP2210600A1 (fr) * 2007-10-10 2010-07-28 Kyowa Hakko Bio Co., Ltd Préparation orale à action rapide pouvant augmenter le taux d'arginine dans le sang contenant de la citrulline et de l'arginine
WO2019183028A1 (fr) * 2018-03-20 2019-09-26 Pro Phase, Inc. Produit nutritionnel et son procédé d'utilisation
WO2020231906A1 (fr) * 2019-05-10 2020-11-19 Bgs Holdings Llc Formulations de compléments alimentaires et pour le sport

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Nitrate salts vs beetroot: How do they compare nutritionally? | Prospector", 3 November 2017 (2017-11-03), pages 1 - 5, XP055791562, Retrieved from the Internet <URL:https://knowledge.ulprospector.com/7381/fbn-sports-nutrition-supplements-formulating-nitrate-salts-vs-beetroot/> [retrieved on 20210330] *
DATABASE FSTA [online] FSTA; 1 February 2017 (2017-02-01), ROUX-MALLOUF T LE ET AL: "FS-2017-07-Ge2883 Effect of acute NO pathway supplementation on flow mediated dilation of the lower limb assessed by near infrared spectroscopy.", XP055791387, Database accession no. FS-2017-07-Ge2883 *
DATABASE GNPD [online] MINTEL; 4 December 2015 (2015-12-04), ANONYMOUS: "Male Physical Response Nitric Oxide Performance Booster", XP055791271, retrieved from www.gnpd.com Database accession no. 3586061 *
DATABASE GNPD [online] MINTEL; 7 September 2018 (2018-09-07), ANONYMOUS: "Pre-Workout Boost", XP055791278, retrieved from https://www.gnpd.com/sinatra/recordpage/5950801/ Database accession no. 5950801 *

Also Published As

Publication number Publication date
EP4192268A1 (fr) 2023-06-14

Similar Documents

Publication Publication Date Title
US10292952B2 (en) Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US9572882B2 (en) Compositions and methods for improving cardiovascular function
US10945979B1 (en) Amino acid compositions to promote endothelial health
US20160303177A1 (en) Nutritional supplement
EP1313488B1 (fr) Compositions et procedes ameliorant les fonctions cardio-vasculaires
CN113498345A (zh) 增强型硝酸盐组合物和使用方法
CN111032037A (zh) 含山奈酚类似物的组合物
US20160303176A1 (en) Nutritional supplement
US20030104107A1 (en) Energy drink formula and method
US20070248648A1 (en) High protein, fatigue reducing powder
WO2022029614A1 (fr) Composition comprenant de l&#39;extrait de betterave rouge
US20220046960A1 (en) Beverage composition and process
US20080108698A1 (en) Nutrient Supplement and Use of the Same
RU2643264C1 (ru) Сухая смесь для спортивного напитка &#34;силавит&#34;
JP2017070271A (ja) 食品またはサプリメント。
Robinson et al. Nutritional and non-medication supplements permitted for performance enhancement
JP7460327B2 (ja) 経口組成物
Forbes Oral l-Arginine Supplementation in Young Males: Endocrinology, Metabolic, and Physiological Responses at Rest and During Exercise
US10799452B2 (en) Sublingual therapeutic solutions and methods
Douligeris et al. Effects of Four Weeks of In-Season Pre-Workout Supplementation on Performance, Body Composition, Muscle Damage, and Health-Related Markers in Basketball Players: A Randomized Controlled Study
Wilborn et al. Ergogenic aids
WO2023016852A1 (fr) Composition d&#39;acides aminés en tant qu&#39;agent vasodilatateur
JP2022552311A (ja) 改善した二日酔い止め組成物、その調製及び使用
KR100523354B1 (ko) 지구성 운동시 피로억제 및 운동 수행 후 면역기능 향상을위한 약학적 조성물 또는 기능성 식품
JP2002363073A (ja) スポーツパフォーマンス

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21763125

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021763125

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE